Clinical Research
Every treatment we prescribe is backed by peer-reviewed clinical evidence. We believe in transparency — here is the science behind our protocols.
Testosterone Replacement Therapy
Testosterone Treatment and Cardiovascular Outcomes
The TRAVERSE trial — a landmark randomized, double-blind, placebo-controlled cardiovascular safety trial of testosterone in 5,204 men — found that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events.
Testosterone and Metabolic Syndrome
A meta-analysis of 32 randomized controlled trials demonstrated that testosterone therapy significantly reduces fasting glucose, insulin resistance (HOMA-IR), triglycerides, and waist circumference in hypogonadal men.
Effects of Testosterone on Body Composition and Muscle Strength
A systematic review of 59 RCTs confirmed that testosterone therapy consistently increases lean body mass and reduces fat mass in men with low testosterone, with strength gains observed in multiple muscle groups.
GLP-1 Weight Loss Medications
Semaglutide 2.4 mg for Weight Management (STEP 1)
The STEP 1 trial showed that once-weekly semaglutide 2.4 mg resulted in a mean body-weight reduction of 14.9% over 68 weeks in adults with overweight or obesity, compared to 2.4% with placebo.
Tirzepatide for Weight Management (SURMOUNT-1)
The SURMOUNT-1 trial demonstrated that tirzepatide achieved up to 22.5% body weight reduction over 72 weeks in adults with obesity, making it one of the most effective pharmacological weight loss treatments ever studied.
Long-term Cardiovascular Outcomes with Semaglutide (SELECT)
The SELECT trial found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease, independent of diabetes status.
Erectile Dysfunction Treatments
Efficacy of PDE5 Inhibitors: A Comprehensive Meta-Analysis
A meta-analysis of 82 randomized controlled trials involving over 47,000 men confirmed that PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are highly effective and well-tolerated for the treatment of erectile dysfunction across all severity levels.
Combination Therapy for Erectile Dysfunction
A review of clinical evidence supports that combination PDE5 inhibitor formulations can improve onset time and patient satisfaction compared to single-agent therapy, particularly in men who have not responded optimally to monotherapy.
ED as an Early Marker of Cardiovascular Disease
A prospective cohort study of over 95,000 men found that erectile dysfunction is an independent predictor of future cardiovascular events, underscoring the importance of early evaluation and treatment.
NAD+ and Anti-Aging
NAD+ Precursors and Cellular Aging
Research has demonstrated that NAD+ levels decline with age and that supplementation with NAD+ precursors (NMN, NR) can restore cellular NAD+ levels, improve mitochondrial function, and activate sirtuins — a family of proteins linked to longevity.
Nicotinamide Mononucleotide (NMN) Safety in Humans
A randomized, double-blind clinical trial found that oral NMN supplementation at doses up to 1,200 mg/day was safe and well-tolerated in healthy adults, with significant increases in blood NAD+ levels observed.
Sermorelin and Growth Hormone Secretion
Clinical studies show that sermorelin acetate effectively stimulates natural growth hormone secretion, improving body composition, sleep quality, and skin elasticity in adults with age-related GH decline — without the risks of exogenous HGH.
Our Commitment to Evidence-Based Medicine
At YouthFuel, every protocol is designed and reviewed by licensed physicians who follow current clinical guidelines. We continuously update our treatment approaches as new evidence emerges. Your health decisions should be informed by science, not marketing.
Start Your Free AssessmentReady to feel like yourself again?
Take our free assessment and get a personalized treatment recommendation from a board-certified physician. No commitment, no credit card, no waiting rooms.
Questions? Call us at 239-217-1535